Adherence: Addressing Pharma’s Last-Mile Problem
Pharma’s continued dependence on tactics such as raising drug prices to hit profit targets just aren’t sustainable long-term. Further, price increases – responsible for 100 percent of pharma’s 2016 earnings per share (EPS) growth – do not improve patient outcomes or save lives.